Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(aEuro)

Files in this item

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics